세계의 수두 백신 시장 보고서(2025년)

Chickenpox vaccines stimulate the immune response, triggering antibody production against varicella-zoster viruses, preventing future infections. The virus causes highly contagious chickenpox (VZV).

The primary types of chickenpox vaccines are the monovalent varicella vaccine and the combination varicella vaccine. The monovalent varicella vaccine contains a live, weakened virus highly effective in generating antibodies, with a single dose inducing antibody formation in about 97% of school-aged recipients. These vaccines have diverse applications, including immunization against mumps, measles, rubella, varicella, herpes zoster, and chickenpox. They are utilized across various end-users such as hospitals, clinics, and other medical settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The chickenpox vaccine market research report is one of a series of new reports from The Business Research Company that provides chickenpox vaccine optical components market statistics, including chickenpox vaccine optical components industry global market size, regional shares, competitors with a chickenpox vaccine optical components market share, detailed chickenpox vaccine optical components market segments, market trends and opportunities, and any further data you may need to thrive in the chickenpox vaccine optical components industry. This chickenpox vaccine optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chickenpox vaccine market size has grown strongly in recent years. It will grow from $3.57 billion in 2024 to $3.76 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to vaccine development, regulatory approvals, disease incidence, vaccination policies, public health initiatives.

The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to public perception and trust, pandemic preparedness, research and development, emerging market demand, healthcare infrastructure development. Major trends in the forecast period include vaccine education campaigns, adverse event monitoring, vaccine pricing strategies, advanced innovation, use of AI.

The forecast of 6.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. pediatric care by increasing the cost of varicella zoster virus vaccines sourced from Japan and Belgium, thereby reducing childhood immunization rates and elevating preventable disease management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chickenpox is anticipated to drive growth in the chickenpox vaccine market. Chickenpox is a highly contagious disease caused by the varicella-zoster virus (VZV), characterized by a fluid-filled rash that is intensely itchy. The rising number of chickenpox cases necessitates more varicella vaccinations, boosting demand for chickenpox vaccines. For instance, in October 2023, a report by the National Library of Medicine (NLM), a US-based biomedical library, shared findings from a study on GP consultations for chickenpox from September 2016 to December 2022, revealing an average weekly rate of 3.4 per 100,000 people in England, with consistent peaks between weeks 13 and 15 each year. However, during the COVID-19 pandemic, typical seasonal peaks were absent, likely due to social distancing and lockdown measures. In 2022, consultation rates increased among children under 1 year old compared to pre-pandemic years, suggesting altered transmission patterns. Therefore, the rising prevalence of chickenpox is driving the demand for chickenpox vaccines.

The rising awareness of vaccination benefits is expected to propel the chickenpox vaccine market. Vaccination involves introducing weakened or inactive forms of a virus or bacteria into the body to build immunity. Increased awareness about the chickenpox vaccine promotes higher vaccination rates, which help reduce disease incidence. For example, in November 2022, the World Health Organization (WHO) released its Global Vaccine Market Report 2022, highlighting that limited vaccine supply and unequal distribution contribute to global health disparities. The report noted that approximately 16 billion vaccine doses, valued at $141 billion, were supplied globally, with COVID-19 vaccines being a significant driver of this increase. Consequently, rising awareness of vaccination benefits is bolstering the chickenpox vaccine market.

Novel drug developments are a key trend gaining traction in the chickenpox vaccine market. Leading companies in this market are focusing on developing new drugs with enhanced efficacy and innovative derivatives to maintain their market position. For example, in November 2022, Sinovac Biotech Ltd., a China-based vaccine research, development, and manufacturing company, announced that the World Health Organization (WHO) granted prequalification for its live attenuated chickenpox (varicella) vaccine, marking it as the world's first varicella vaccine to receive this designation. The varicella vaccine, derived from the Oka strain, is manufactured in SINOVAC's exclusive Human Diploid Cell (SV-1 strain) through virus cultivation, stabilizer addition, and freeze-drying. A phase III efficacy study showed a seroconversion rate of 97.1% in children aged 1 to 12 years, the vaccine's efficacy against varicella and breakthrough varicella was 87.1% and 89.2%, respectively. The vaccine provides complete protection against both mild and severe cases.

Leading companies in the chickenpox vaccine market are prioritizing research and development (R&D) investments to introduce advanced vaccine formulations. R&D investments refer to funds allocated by organizations, including companies, governments, and research institutions, for innovation and advancement in specific fields. For example, in February 2022, as reported by GOV.UK, the UK government committed £10 million to vaccine research targeting epidemic prevention in developing countries. The UK Vaccine Network selected 22 research projects to address viruses such as Ebola, Lassa fever, and Zika.

In July 2022, GC LabCell, a prominent biotechnology company based in South Korea, finalized a definitive merger agreement with GC Cell Corporation, also based in South Korea, which specializes in the production of chickenpox vaccine. This strategic merger unites two distinguished biopharmaceutical entities from South Korea, each with its unique strengths and portfolios. The combined entity benefits from highly complementary portfolios, bolstered by an extensive cell therapy research and development pipeline. Additionally, the merger leverages cutting-edge manufacturing capabilities, positioning the consolidated company to expedite its growth trajectory significantly. This strategic move is expected to foster accelerated growth and enhance value creation within the biopharmaceutical landscape.

Major companies operating in the chickenpox vaccine market include Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics

North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chickenpox vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chickenpox vaccines market consists of sales of single-antigen varicella vaccines and mixed-antigen varicella vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chickenpox Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chickenpox vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chickenpox vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chickenpox vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine: Monovalent Varicella Vaccine; Combination Varicella Vaccine
• 2) By Application: Mumps, Measles, Rubella, And Varicella Immunization; Herpes Zoster Immunization; Chickenpox Vaccination
• 3) By End-Users: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine
• 2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, And Varicella (MMRV) Vaccine
• Companies Mentioned: Merck & Co.; Sanofi Pasteur; Takeda Pharmaceutical Company Limited; CSL Limited; Pfizer Inc.; Seqirus; Serum Institute of India Pvt. Ltd.; Bharat Biotech; Emergent BioSolutions Inc.; Hualan Biological Engineering Inc.; Shenzhen Kangtai Biological Products Co.; Ltd.; Chongqing Zhifei Biological Products Co.; Ltd.; Beijing Minhai Biotechnology Co.; Ltd.; Adimmune Corporation; Biological E. Limited; Walvax Biotechnology Co.; Ltd.; Zydus Cadila; Indian Immunologicals Ltd.; Panacea Biotec Ltd.; Bio Farma; PT Kalbe Farma Tbk; CanSino Biologics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chickenpox Vaccine Market Characteristics

3. Chickenpox Vaccine Market Trends And Strategies

4. Chickenpox Vaccine Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chickenpox Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chickenpox Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chickenpox Vaccine Market Growth Rate Analysis
• 5.4. Global Chickenpox Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chickenpox Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chickenpox Vaccine Total Addressable Market (TAM)

6. Chickenpox Vaccine Market Segmentation

• 6.1. Global Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent Varicella Vaccine
• Combination Varicella Vaccine
• 6.2. Global Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mumps
• Measles
• Rubella And Varicella Immunization
• Herpes Zoster Immunization
• Chickenpox Vaccination
• 6.3. Global Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Users
• 6.4. Global Chickenpox Vaccine Market, Sub-Segmentation Of Monovalent Varicella Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Varicella Vaccine
• 6.5. Global Chickenpox Vaccine Market, Sub-Segmentation Of Combination Varicella Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Measles
• Mumps
• Rubella And Varicella Immunization

7. Chickenpox Vaccine Market Regional And Country Analysis

• 7.1. Global Chickenpox Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chickenpox Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chickenpox Vaccine Market

• 8.1. Asia-Pacific Chickenpox Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chickenpox Vaccine Market

• 9.1. China Chickenpox Vaccine Market Overview
• 9.2. China Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chickenpox Vaccine Market

• 10.1. India Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chickenpox Vaccine Market

• 11.1. Japan Chickenpox Vaccine Market Overview
• 11.2. Japan Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chickenpox Vaccine Market

• 12.1. Australia Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chickenpox Vaccine Market

• 13.1. Indonesia Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chickenpox Vaccine Market

• 14.1. South Korea Chickenpox Vaccine Market Overview
• 14.2. South Korea Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chickenpox Vaccine Market

• 15.1. Western Europe Chickenpox Vaccine Market Overview
• 15.2. Western Europe Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chickenpox Vaccine Market

• 16.1. UK Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chickenpox Vaccine Market

• 17.1. Germany Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chickenpox Vaccine Market

• 18.1. France Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chickenpox Vaccine Market

• 19.1. Italy Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chickenpox Vaccine Market

• 20.1. Spain Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chickenpox Vaccine Market

• 21.1. Eastern Europe Chickenpox Vaccine Market Overview
• 21.2. Eastern Europe Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chickenpox Vaccine Market

• 22.1. Russia Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chickenpox Vaccine Market

• 23.1. North America Chickenpox Vaccine Market Overview
• 23.2. North America Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chickenpox Vaccine Market

• 24.1. USA Chickenpox Vaccine Market Overview
• 24.2. USA Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chickenpox Vaccine Market

• 25.1. Canada Chickenpox Vaccine Market Overview
• 25.2. Canada Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chickenpox Vaccine Market

• 26.1. South America Chickenpox Vaccine Market Overview
• 26.2. South America Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chickenpox Vaccine Market

• 27.1. Brazil Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chickenpox Vaccine Market

• 28.1. Middle East Chickenpox Vaccine Market Overview
• 28.2. Middle East Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chickenpox Vaccine Market

• 29.1. Africa Chickenpox Vaccine Market Overview
• 29.2. Africa Chickenpox Vaccine Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chickenpox Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chickenpox Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chickenpox Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Chickenpox Vaccine Market Competitive Landscape
• 30.2. Chickenpox Vaccine Market Company Profiles
  • 30.2.1. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. CSL Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Chickenpox Vaccine Market Other Major And Innovative Companies

• 31.1. Seqirus
• 31.2. Serum Institute of India Pvt. Ltd.
• 31.3. Bharat Biotech
• 31.4. Emergent BioSolutions Inc.
• 31.5. Hualan Biological Engineering Inc.
• 31.6. Shenzhen Kangtai Biological Products Co. Ltd.
• 31.7. Chongqing Zhifei Biological Products Co. Ltd.
• 31.8. Beijing Minhai Biotechnology Co. Ltd.
• 31.9. Adimmune Corporation
• 31.10. Biological E. Limited
• 31.11. Walvax Biotechnology Co.Ltd.
• 31.12. Zydus Cadila
• 31.13. Indian Immunologicals Ltd.
• 31.14. Panacea Biotec Ltd.
• 31.15. Bio Farma

32. Global Chickenpox Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chickenpox Vaccine Market

34. Recent Developments In The Chickenpox Vaccine Market

35. Chickenpox Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Chickenpox Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chickenpox Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chickenpox Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer